Drug-safety review | 1 November 2026. The Central Drugs Standard Control Organisation (CDSCO) lists fludrocortisone — hypokalaemia in its adverse-drug-reaction (ADR) notification register, with a 21 September 2026 release date. This article explains the pharmacology, clinical implications and monitoring priorities. The notification is a safety communication, not an announcement that fludrocortisone has been banned or recalled.
What does fludrocortisone do?
Fludrocortisone is a potent synthetic mineralocorticoid. At the renal distal nephron it promotes sodium retention and potassium excretion. The physiological effect can support patients with mineralocorticoid deficiency, but excessive mineralocorticoid activity may lead to hypokalaemia, fluid retention, oedema and hypertension. The medicine is used under specialist-directed treatment plans; indications and local product labels must be checked.
Why potassium can fall
Enhanced renal sodium reabsorption is coupled to greater urinary potassium loss. Low potassium can affect skeletal muscle, smooth muscle and cardiac electrical activity. Risk may be greater when there are additional potassium losses, such as vomiting or diarrhoea, or concurrent medications that increase potassium excretion.
Clinical manifestations to recognize
- Muscle weakness, cramps or fatigue.
- Constipation and, in severe cases, impaired muscle function.
- Palpitations, rhythm disturbances or ECG changes when potassium depletion is clinically significant.
- Associated fluid retention, elevated blood pressure or peripheral oedema suggesting excessive mineralocorticoid effect.
Symptoms are not sufficiently sensitive to rule out electrolyte disturbance. A potassium measurement is needed when clinically indicated.
Monitoring in routine practice
- Before and during treatment: review blood pressure, body weight, oedema, serum potassium and renal function as indicated by the prescribing specialist.
- Medication reconciliation: identify diuretics, laxative misuse, systemic corticosteroids and other agents that may complicate potassium balance.
- Clinical review: evaluate new weakness, cramps, palpitations or substantial blood-pressure/weight changes rather than automatically attributing them to the underlying disease.
- Escalation: significant symptoms, suspected arrhythmia or severe biochemical hypokalaemia warrant urgent assessment and appropriate ECG/electrolyte management.
- Do not abruptly alter replacement therapy: changing fludrocortisone without a plan may destabilize patients who need mineralocorticoid replacement.
How to document a suspected ADR
Record the indication, product and strength, actual prescribed regimen, start date, concurrent medicines, potassium results and trends, renal function, blood pressure, ECG findings if available, management and outcome. A temporal association is not definitive proof of causality; consider alternative causes. Report suspected ADRs through the applicable Indian Pharmacovigilance Programme (PvPI) route.
Important interpretation of the CDSCO entry
The publicly accessible CDSCO ADR index identifies the drug, reaction and release date. Without independently reviewing the full attached notice, this article does not claim a newly mandated laboratory interval, new contraindication, exact incidence, or regulatory withdrawal. Monitoring frequency and management must be individualized.
Primary references
- CDSCO ADR notifications register (Fludrocortisone–Hypokalaemia, 21 September 2026)
- DailyMed official US product labeling, revised May 2025 (mechanism and precautions; local Indian label governs)
For clinicians: this is a pharmacovigilance explainer, not a patient-specific dose or potassium-replacement protocol.